Trial Profile

A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ciltacabtagene autoleucel (Primary) ; Bortezomib; Cyclophosphamide; Daratumumab; Dexamethasone; Dexamethasone; Fludarabine; Lenalidomide
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms CARTITUDE-2
Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

17 Jul 2024 Planned number of patients changed from 157 to 237.
17 Jul 2024 Status changed from active, no longer recruiting to recruiting.
18 Jun 2024 Planned primary completion date changed from 30 May 2025 to 1 Dec 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com